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A B S T R A C T
Obesity is a worldwide health problem with epidemic proportions that has been associated with atrial
ﬁbrillation (AF). Even though the underlying pathophysiological mechanisms have not been completely
elucidated, several experimental and clinical studies implicate obesity in the initiation and perpetuation
of AF. Of note, hypertension, diabetes mellitus, metabolic syndrome, coronary artery disease, and
obstructive sleep apnea, represent clinical correlates between obesity and AF. In addition, ventricular
adaptation, diastolic dysfunction, and epicardial adipose tissue appear to be implicated in atrial electrical
and structural remodeling, thereby promoting the arrhythmia in obese subjects. The present article
provides a concise overview of the association between obesity and AF, and highlights the underlying
pathophysiological mechanisms.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Atrial ﬁbrillation (AF) is the commonest arrhythmia in clinical
practice and is associated with increased cardiovascular morbidity
and mortality [1,2]. Obesity represents a novel risk factor for AF
associated with a 50% increased incidence [3]. Even though the
pathophysiological substrates and links implicating obesity in AF
occurrence are not completely understood, various comorbidities
as well as ventricular adaptation and epicardial adipose tissue
appear to play a crucial role (Fig. 1). This article provides a
comprehensive and critical overview of the mechanisms facilita-
ting AF initiation and perpetuation in obese subjects.
Obesity as a risk factor for atrial ﬁbrillation
A mounting body of evidence indicates an association between
obesity and AF [3–17]. Indeed, obese individuals have an almost
50% increased risk for AF compared to nonobese [3,4]. Speciﬁcally,
Wang et al. observed a 4% increase in AF risk per 1-U increase in
body mass index (BMI), at a mean follow-up of 13.7 years [3]. The
Danish Diet, Cancer, and Health Cohort Study indicated a higher
risk of AF associated with increased anthropometric measure-
ments such as height, weight, BMI, hip circumference, and waist
circumference, as well as with increased bioimpedance-derived
measures of body fat mass, body fat percentage, and lean body
mass [7]. It has also been reported that overweight and obese
young men have more than a 2-fold risk of AF compared with
young men of normal weight [16], while obesity is an independent
risk factor for AF among young and essentially healthy fertile
women despite the low incidence of the arrhythmia [11]. Resistin,
a hormone that is abundantly secreted from lipid cells, is linked to
type 2 diabetes and obesity. Obese people appear to have higher
resistin levels compared to healthy subjects and this increase
correlates with BMI [18]. Furthermore, patients with paroxysmal
and persistent AF were found to have higher resistin levels
compared to controls [18]. In cardiothoracic surgery cohorts, the
risk for postoperative AF in obese patients is also increased
compared to nonobese [19,20], and this risk increases progres-
sively with rising BMI [20]. In a recent meta-analysis, Hernandez
et al. showed that obese patients undergoing cardiac operations
have a modestly higher risk of postoperative AF, whereas the
association between obesity and postoperative AF does not vary by
the type of cardiac operation [21]. Several studies have alsoOBESITY
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Fig. 1. Graphical depiction of pathophysiological reported that BMI independently predicts progression from
paroxysmal to permanent AF [22–24]. In women without AF at
baseline increasing adiposity was preferentially associated with
the early development of non-paroxysmal AF [23]. Additionally, for
people whose initial AF episode terminates, the beneﬁts of
lowering BMI may include a lower risk for future development
of permanent AF [24]. In this context, Guglin et al. demonstrated
that obesity is associated with a higher recurrence rate and greater
burden of AF compared to nonobese patients [25]. After multivari-
ate analysis it was demonstrated that left atrial (LA) size but not
BMI was an independent predictor of recurrence and AF burden,
but given the correlation between LA size and BMI the effects of
increased BMI on atrial size possibly reﬂect the atrial remodeling
observed in this setting [25]. Another recent meta-analysis
reported that elevated BMI is signiﬁcantly associated with AF
recurrence after pulmonary vein isolation [26]. Interestingly, BMI
has been incorporated in validated risk scores for AF developed in
community-based cohorts [27–29]. Therefore, the impact of
increased BMI on AF risk appears to be well established.
Pathophysiological links between obesity in atrial ﬁbrillation
Clinical correlates between obesity and atrial ﬁbrillation
Several potential mechanisms link obesity and AF (Fig. 1).
Common pathophysiological pathways appear to be operative in
obesity, AF, and speciﬁc clinical conditions such as hypertension,
diabetes mellitus (DM), metabolic syndrome (MS), coronary artery
disease, and obstructive sleep apnea (OSA).
Hypertension
An increasing body of evidence supports the concept that
hypertension is an important risk factor for AF [5,30–33], increasing
the risk of the arrhythmia by almost 2-fold [34]. Hypertension
causes reduction of left ventricular (LV) compliance, diastolic
dysfunction, and LV hypertrophy (LVH). LVH increases LV stiffness,
wall stress and ﬁlling pressure, decreases coronary ﬂow reserve,
and activates the sympathetic nervous system as well as the
renin–angiotensin–aldosterone system (RAAS) [35,36]. The mecha-
nisms involved in hypertension-associated AF include triggering
activity, atrial electrical and structural remodeling, and inﬂamma-
tion. Stretch impulses depolarize the myocyte membrane within
milliseconds and induce after-polarizations, which produceATRIAL 
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ATRIAL
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links between obesity and atrial ﬁbrillation.
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ed by calcium inﬂuxes through stretch-activated calcium channels
[37]. Changes in atrial electrical properties occur early in hyperten-
sive heart disease, preceding the appearance of LVH and LA
enlargement [38]. There are two distinct abnormalities of electrical
properties: the prolongation of atrial conduction velocity and the
decrease in atrial refractoriness. The wavelength is a product of
refractory period and conduction velocity (WL = CV  RP). The
shortening of refractoriness, in combination with a decrease in
conduction velocity, results in a shorter atrial wavelength, thus
favoring reentry [39]. In an experimental model, hypertension
increased AF inducibility through a decrease in ICaL and an increase in
atrial ﬁbrosis [40]. Cha´vez et al. investigated the relationship
between blood pressure, LV mass index, and P-wave dispersion in a
pediatric population and reported increased P-wave dispersion in
pre- and hypertensive children, and a dependence of the P-wave
dispersion on the LV mass index [41]. In the same line, Francia et al.
reported that a simple measurement of P-wave duration in lead aVR
allows effective identiﬁcation of AF risk in a population of
hypertensive patients [42].
Activation of the RAAS plays a key role in arterial hypertension
and LVH representing an important pathway leading to AF.
Stretching of atrial myocardiocytes causes an increase in the
expression of angiotensin-converting enzyme (ACE) in the atria
and consequently increases production of angiotensin II and
aldosterone which further promote myocyte hypertrophy, ﬁbro-
sis, apoptosis, and vasoconstriction [43]. The last part of this
cascade is aldosterone, which also stimulates ﬁbroblasts and
promotes ﬁbrosis through its action on mitogen-activated kinases
[44]. In experimental models, ventricular pressure overload
induces atrial remodeling, including hypertrophy, dilatation
and inﬂammation [45]. LA enlargement is present in a relevant
proportion of the hypertensive population [46] while increased LA
volume and impaired LA active emptying functions have been
associated with paroxysmal AF in untreated hypertensive
patients [47]. In a recent study, Conen et al. reported that in
women, the body weight is associated with AF only in the presence
of LA enlargement [48].
Inﬂammation appears to be involved in hypertension-associat-
ed AF. Experimental data indicate that angiotensin II activates
various inﬂammatory mediators, such as C-reactive protein (CRP),
tumor necrosis factor-a (TNFa), and interleukin-6 (IL-6), and
stimulates the recruitment and inﬁltration of neutrophils
[49,50]. It has also been demonstrated that hypertensive patients
exhibit shortened pulmonary vein event-related potentials with
increased dispersion, prolonged conduction time, and increased
pulmonary vein diameter [51]. In an interesting study, Deng et al.
sought to determine the mRNA expressions of peroxisome
proliferator-activated receptor alpha and beta (PPARa, PPARb)
in peripheral blood mononuclear cells of non-valvular hyperten-
sive AF patients and elucidate its possible role in the pathogenesis
of AF [52]. It was shown that increased inﬂammatory cytokines
(TNFa, IL-6, IL-1) were associated with atrial remodeling leading to
the development of AF while PPARa was negatively correlated
with these inﬂammatory cytokines [52]. Notably, ACE inhibitors
and angiotensin receptor blockers (ARBs) appear to be effective in
primary [53] and secondary [54,55] prevention of AF.
Diabetes mellitus
DM, poor glycemic control, and hemoglobin A1c levels have
been independently associated with new onset of AF. The
Framingham Heart Study reported that DM is signiﬁcantly
associated with AF risk in both sexes [34]. In the same line,
Huxley et al. showed that diabetes, hemoglobin A1c level, and poor
glycemic control are independently associated with increased risk
of AF [56]. Notably, a recent meta-analysis indicated that DM wasassociated with about 40% increased risk for AF [57]. Autonomic,
electrical, electromechanical and structural remodeling, oxidative
stress, connexin remodeling, and glycemic ﬂuctuations appear to
be implicated in AF occurrence in patients with DM [58]. Otake
et al. established a streptozotocin-induced DM rat model showing
that sympathetic stimulation increased the incidence of AF in DM
rats but not in controls [59]. Sympathetic stimulation signiﬁcantly
shortened the effective refractory period (ERP) of atrial cells in both
groups, but the heterogeneity of atrial ERP was increased only in
DM rats [59]. Interestingly, immunohistochemical staining of the
right atrium aimed at determining the distribution of sympathetic
nerves, revealed that tyrosine hydroxylase positive nerves were
signiﬁcantly more heterogeneous in DM rats than in controls,
whereas the heterogeneity of acetylcholine esterase positive
nerves did not differ between the two groups [59]. In the same
model, Watanabe et al. demonstrated that diabetic atrium is
characterized by increased conduction slowing, heterogeneity of
conduction slowing, prolongation of action potential duration
(APD), increase in spatial dispersion, frequency-dependent short-
ening of APD, and increased incidence of APD alternans [60]. In a
recent experimental protocol using an alloxan-induced diabetic
rabbit model, hyperglycemia or DM contributed to atrial dilation
and interstitial ﬁbrosis, ionic remodeling, and vulnerability to AF,
resulting in the initiation and perpetuation of AF [61]. Advanced
glycation end products (AGEs) and AGE receptors (RAGEs) (the
AGERAGE system) mediate the diffuse interstitial ﬁbrosis of atrial
myocardium in DM rats through upregulation of growth factors
promoting structural remodeling [62]. Remarkably, AGE inhibitors
can downregulate the expression of growth factors and signiﬁ-
cantly inhibit the progression of DM-induced atrial ﬁbrosis [62]. In
another study, Chao et al. investigated the atrial substrate
properties and clinical outcome of catheter ablation in patients
with paroxysmal AF and abnormal glucose metabolism [63]. It was
evident that activation time of both atria was signiﬁcantly longer,
bipolar voltage was signiﬁcantly decreased in the abnormal
glucose metabolism group, and AF recurrence rate was greater
in patients with abnormal glucose metabolism than in those
without [63]. In a streptomycin-induced diabetic rat model the
expression of CX43 in the diabetic group was signiﬁcantly higher
than CX40, indicating CX43 rather than CX40 may become the
main type of gap junction protein in the atrium [60]. Interestingly,
gene therapy targeting connexins preserves conduction and
prevents AF [64].
It has long been argued that glycemic ﬂuctuations rather than
the hyperglycemic state itself promote AF [65]. In experimental
models, hypoglycemia has been shown to increase vulnerability to
AF. Speciﬁcally, in a streptozotocin-induced diabetic rat model, it
was demonstrated that glucose ﬂuctuations increase the incidence
of AF by promoting cardiac ﬁbrosis [66]. Increased reactive oxygen
species levels caused by upregulation of thioredoxin-interacting
protein (Txnip) and NADPH oxidase expression may be a
mechanism whereby glucose ﬂuctuations induce ﬁbrosis [66].
Metabolic syndrome
There are several deﬁnitions of MS, but the key features are
abdominal obesity, elevated blood pressure, dyslipidemia (high
triglycerides and low high-density lipoprotein cholesterol), and
insulin resistance [13]. The majority of epidemiological and
observational studies conducted in general populations have
conﬁrmed previous speculations [67] and proved that subjects
with MS have a greater likelihood of AF [12,13,68]. Several studies
reported that MS is associated with atrial remodeling, including
prolonged P-wave indices such as P-wave dispersion (PWD) and
P-wave maximum duration (Pmax) [69,70], electromechanical
interval [71], atrial synchronicity [72], mitochondrial dysfunction
[73], and increased LA size [74]. Wang et al. investigated the
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and indicated that Pmax and PWD were increased in patients with
MS compared to controls without MS [70]. Also, PWD was
independently associated with insulin resistance, but not with
other factors such as waist circumference, BMI, blood pressure, LA
size, and LV diastolic function [70]. Several pathophysiological
mechanisms involved in insulin resistance-induced prolongation
of PWD and Pmax have been proposed. Insulin resistance causes
diastolic dysfunction [75] and upregulation of angiotensin II
receptor expression [76]. The activation of the RAAS causes atrial
ﬁbrosis, cardiomyocyte apoptosis, and elicits reactive oxygen
species generation [77]. Furthermore, the sympathetic nervous
system is overactive in insulin-resistant states [78], resulting in a
signiﬁcant prolongation of P-wave duration and PWD [79,80]. In
addition, insulin resistance promotes activation of many proin-
ﬂammatory transcription factors [81] and induces the generation
of reactive oxygen species [82,83].
Indeed, inﬂammation and oxidative stress have been implicat-
ed in the pathogenesis of AF [84–86]. A recent study showed
that the reduction of AF recurrence and severity in patients with
MS is associated with a decrease of PWD, and possibly related to
the improvement in atrial ﬁbrosis and electrical remodeling
[87]. In this context, Hung et al. investigated the association
between electromechanical interval – deﬁned as the time from
initiation of P-wave deﬂection to peak of mitral inﬂow Doppler A
wave (PA-PDI) – and MS, and concluded that PA-PDI intervals were
longer in patients with MS compared to those without MS, and
tracked with insulin resistance [71]. Moreover, patients with MS
without known atrial arrhythmia were shown to have impaired
intra- and interatrial synchronicity [72]. In a recent study, the
presence of an association between pre-operative mitochondrial
dysfunction of the atrial myocardium and AF occurrence after
cardiac surgery in patients with MS was evident [73].
Coronary artery disease
Atrial ischemia appears to be a prevalent intermediate link
between obesity and AF. In experimental models, Lammers et al.
reported that hypoxia of isolated superfused rabbit atrial
preparations results in a transient increase in atrial ERPs and a
decrease in conduction velocity [88]. Additional experimental
data indicated that proximal right coronary artery occlusion
which causes posterior left ventricular and left atrial ischemia
reduces atrial ERPs—an effect not altered by the adenosine
triphosphate (ATP)-dependent K+-channel blocker glibenclamide
[89]. In the same line, Sinno et al. reported that atrial ischemia
creates an appropriate substrate for AF maintenance, apparently
by causing local conduction slowing favoring reentry [90]. Nishida
et al. further indicated that an 8-day chronic right atrial infarction
in a canine model is also a substrate for AF initiation and
maintenance [91]. In the clinical setting, Skalidis et al. reported
atrial myocardial perfusion abnormalities and coronary ﬂow
reserve impairment in patients with lone AF [92]. In a recent
study, it was reported that coronary artery disease of atrial
branches is an independent predictor of new-onset AF in acute
myocardial infarction patients [93]. From a mechanistic point of
view, both spontaneous focal discharges and reentrant circuits are
likely to initiate and maintain AF. In addition, it could be
speculated that atrial ischemia-infarction, which may remain
silent for extended periods, contributes to preclinical remodeling
conducive to AF [94].
Obstructive sleep apnea
The prevalence of AF is increased in patients with OSA, even in
the absence of underlying cardiac disease. On the other hand, in
obese cohorts the prevalence of OSA extends up to 90% [95]. The
Sleep Heart Study demonstrated that the risk of AF is four timesgreater in patients with sleep disordered breathing (obstructive
and central sleep apnea) compared to patients with no sleep
disordered breathing [96]. The mechanisms involved in sleep
apnea-associated AF include apnea-induced hypoxia and hyper-
capnia, intrathoracic pressure changes, heightened sympathetic
activity, and systemic inﬂammation. Hypoxia and hypercapnia
affect sympathetic nerve activity and cause vasoconstriction and,
as a result, hypertension [97] that is a known risk factor for AF
[98]. The severity of OSA, as measured by nocturnal oxygen
desaturations, correlates with the prevalence of AF [99] and
predicts AF within approximately 5 years of diagnosis of OSA
[6]. Recurrent nocturnal apneas during sleep in OSA are
accompanied by chemoreceptor-induced sympathetic activation
and/or decreased parasympathetic tone manifested as impaired
vagal input, diminished baroreﬂex sensitivity, and impairment of
the parasympathetic components of heart rate variability [100]. In
fact, Noda et al. reported that in OSA patients, nocturnal plasma
norepinephrine levels were correlated with the duration of oxygen
desaturation [101]. Even though decreased parasympathetic
activation predominates in severe OSA patients, there is evidence
of rare increased parasympathetic activation toward the end of
apneas at least in some of them. This is supposed to occur as an
oxygen conservation reﬂex (known as the ‘diving’ reﬂex) in
response to apnea-induced hypoxemia and is mediated through
increased vagal tone [99]. It is believed that the reduced
refractoriness of the cardiac conducting system during bradycardia
may predispose to focal electrical discharges within the pulmonary
vein ostia, thereby leading to AF [102]. Notably, Linz et al. showed
that atrial effective refractory period was shortened with applied
negative tracheal pressure in a swine model, resulting in greater
AF inducibility [103]. However, some studies showed that in lone
AF patients the onset of the arrhythmia is associated with a change
in autonomic balance without an increase in vagal or sympathetic
tone alone [104,105]. In a recent study, Fujiki et al. showed a high
prevalence of cyclical variation in heart rate before nocturnal AF
episodes and suggested that sleep apnea may play a role in the
onset of nighttime AF [106].
There is also increasing evidence that OSA results in atrial
electrical and structural remodeling. The atria of OSA patients were
shown to have extensive areas of low voltage or electrical silence
and conduction abnormalities, as indicated by prolonged P-wave
durations, slower atrial conduction velocity, and sinus node
recovery times [107]. The repetitive occlusions of the upper
airway during sleep generate substantial shifts in intrathoracic
pressure with gradients up to 65 mmHg [108]. These gradients
are transmitted from the thorax to the thin-walled atria and the
transmural forces are thought to contribute to atrial chamber
enlargement and ﬁbrosis, as both are known risk factors for AF
[102]. Moreover, it has been suggested that these transmural forces
may be important in tissue stretch and remodeling at the
pulmonary vein ostia [102], a known focal source of AF
[109]. Remarkably, OSA induces selective atrial ﬁbrosis in a
murine model which can be mediated in part by the systemic and
local inﬂammation as well as by decreased collagen-degradation
[110]. Mesenchymal stem cell transplantation prevents atrial
ﬁbrosis in this model suggesting that this intervention can
counterbalance inﬂammation in OSA [110].
Ventricular adaptation and atrial abnormalities
A mounting body of evidence indicates that obesity is
independently associated with LV hypertrophy [111–115] while
BMI is an independent predictor of LA size in adults [116–119]. The
mechanisms of increased LA size are possibly related to the
associated hypertension, volume overload, and LV diastolic
abnormalities. Obese subjects in the Framingham Heart Study
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was associated with the increase in LA size [3]. Interestingly, Abed
et al. used a sheep model to characterize the atrial functional,
structural, and electrophysiological changes accompanying
increasing adiposity [120]. Progressive weight gain resulted in
atrial functional, structural, and electrophysiological remodeling
characterized by increased atrial volumes, LA and systemic
pressures, ventricular mass, and pericardial fat volumes, increased
atrial interstitial ﬁbrosis, inﬂammation, myocardial lipidosis,
progressive conduction abnormalities with slowing of atrial
conduction, and increased conduction heterogeneity. They also
demonstrated an increase in interstitial and cytoplasmic trans-
forming growth factor-b1 (TGF-b1), connective tissue growth
factor (CTGF), and platelet-derived growth factor (PDGF) levels
[120]. Notably, due to the disproportion of progressive hemody-
namic impact of obesity on AF burden, they suggested a direct
pathogenic role of obesity on AF substrate [120]. In this context,
Yagmur et al. reported that low-grade inﬂammation as well as LA
enlargement and early LV diastolic dysfunction prolongs atrial
electromechanical delay in obese subjects [121]. Obesity has been
associated with increased Pmax and PWD, increased prevalence of
interatrial block, and increased AF risk as well [122]. In a recent
cross-sectional study, the association between obesity and the
components of the MS with P-wave indices was evaluated [123]. It
was demonstrated that higher BMI is associated with increased
P-wave indices, such as PR interval, Pmax, and P-wave terminal
force [123]. In addition, P-wave indices were further increased in
participants with MS. A separate examination of the individual
components of the MS revealed that waist circumference and
hypertension were the chief factors responsible for prolongation of
P-wave indices [123]. Notably, a recent study sought to determine
the electrophysiological, hemodynamic, and echocardiographic
characteristics in obese patients with AF [124]. It was indicated
that shortened ERP, slowed conduction in the PV ostia, elevated LA
ﬁlling pressure, LV diastolic dysfunction, impaired LA stretching
and contraction, and enlarged LA volume contribute to the
predisposition and perpetuation of AF in obese patients [124].
Epicardial adipose tissue
The relationship between thickness of epicardial adipose tissue
(EAT) and AF burden has recently been described in several studies.
The Framingham Heart Study reported that pericardial fat volume
predicts AF, independently of other measures of adiposity,
including BMI [125]. However, a highly signiﬁcant correlation
exists between EAT and BMI, waist circumference, or visceral
adipose tissue [126]. It has also been demonstrated that pericardial
fat is highly associated with paroxysmal and persistent AF
independently of traditional risk factors, including LA enlargement
[127]. Other studies, indicate that pericardial fat is associated with
the prevalence and severity of AF, suggesting that EAT volume may
have a speciﬁc prognostic signiﬁcance besides traditional mea-
sures of obesity [128,129]. C¸etin et al. reported that increased EAT
thickness is related to diastolic dysfunction and LA enlargement in
patients with essential hypertension [130]. It is therefore tempting
to speculate that the direct impact of obesity on atrial substrate
may be mediated via EAT [128,129].
Apart from its role in energetic and lipid metabolism, adipose
tissue produces a myriad of bioactive molecules, such as
inﬂammatory mediators and adipocytokines that have been shown
to mediate the effect of visceral fat on other tissues [131]. Among
the cytokines found in abundance in the EAT secretome, activin A
and matrix metalloproteinases (MMPs) may mediate the ﬁbrotic
effect of EAT secretome on atrial myocardium [132]. Indeed, the
supplementation of culture media with recombinant human
activin A reproduced the atrial myocardial ﬁbrosis observed withEAT secretome, and anti-activin A antibody neutralized these
proﬁbrotic effects induced by the EAT secretome [133]. Both
EAT-conditioned medium and activin A induced the expression of
TGF-b1 and -b2 in the atria, which could indirectly contribute to
the proﬁbrotic effect of activin A [133]. MMPs are key regulators of
extracellular matrix homeostasis, including the various collagen
ﬁbers and basement membrane components. During AF, it has been
demonstrated that upregulated activity of several MMPs, speciﬁ-
cally MMP2 and MMP7, accentuates interstitial ﬁbrosis [134].
Losing epicardial layer continuity due to endomysial ﬁbrosis
appears to be one of the major determinants of the complexity of
ﬁbrillatory conduction pathways [135]. In this context, EAT
accumulation is associated with fatty inﬁltration from the
epicardial layer, which advances deep into the myocardium, and
thus contributing to myocardium functional disorganization
and the formation of local arrhythmogenic substrate [136]. EAT
may also affect the atrial cellular components by altering the
proliferation of myoﬁbroblasts and the number of dedifferentiated
and dystrophic myocytes [137,138]. In fact, adipose tissue contains
abundant stem cells located in the stroma fraction [139,140] that
are capable of differentiating not only into adipocytes, but also into
cardiomyocytes [141] or myoﬁbroblasts [142]. Therefore, cardiac
fatty tissue may constitute a source of precursor cells that can
differentiate into myoﬁbroblasts, contributing to atrial structural
remodeling.
Interestingly, EAT contains abundant ganglionated plexi that
seem to play an important role in the initiation and maintenance
of AF. Indeed, stimulation of ganglionated plexi induces focal
ﬁring arising from pulmonary vein and non-pulmonary vein sites
[143], while ablation of the major ganglionated plexi at the
pulmonary vein-atrial entrances eliminates or diminishes AF
inducibility [144]. There is also increasing evidence implicating
inﬂammation in AF development and perpetuation [145]. Inﬂam-
matory markers, such as CRP, have been associated with AF
development, recurrence after cardioversion and thromboem-
bolic risk [146–149]. Other inﬂammatory markers and mediators,
such as TNF-a, IL-2, IL-6, IL-8, and monocyte chemoattractant
protein (MCP)-1, have also been associated with AF [145]. All
these inﬂammatory factors are produced and secreted by EAT in
abundance, speciﬁcally in the setting of ischemic cardiomyopa-
thy, obesity, or diabetes [132]. Besides adipocytes, monocytes can
be a source of inﬂammatory cytokines in EAT [150,151]. Acet et al.
investigated the relationship of echocardiographic epicardial fat
thickness and neutrophil to lymphocyte ratio with different types
of non-valvular AF. Epicardial fat thickness and neutrophil to
lymphocyte ratio were highly associated with types of non-
valvular AF independently of traditional risk factors and appear to
be related to the duration and severity of AF [152]. In a recent
study, Mazurek et al. showed that inﬂammatory activity of fat
located near the left atrium and left main coronary artery,
reﬂected by glucose metabolism of EAT is signiﬁcantly and
strongly linked with AF [153]. It was also demonstrated that the
inﬂammatory activity of EAT measured close to the left atrium and
left main coronary artery was signiﬁcantly greater than that of
subcutaneous or visceral fat [153].
Genetics of atrial ﬁbrillation in obesity
Genetic advances over the past decade have facilitated the
identiﬁcation of mutations and common polymorphisms associat-
ed with AF. Yang et al. investigated whether the polymorphisms of
TaqIB of cholesteryl transfer protein (CETP) gene and 1444 C/T of
CRP gene are associated with non-valvular atrial ﬁbrillation. They
demonstrated that CETP TaqIB (B2 allele as protective factor) and
CRP1444 C/T (T allele as risk factor) genetic polymorphisms may be
associated with non-valvular AF, and that obesity may induce
C.A. Goudis et al. / Journal of Cardiology 66 (2015) 361–369366hereditary susceptibility to non-valvular AF in males [154]. G
protein-coupled inward rectiﬁer K(+) channel 4 (GIRK4) is a G
protein-coupled inward rectiﬁer potassium channel family mem-
ber. Encoded by the KCNJ5, it is widely distributed in the
mammalian heart, brain, and other tissues and organs. Recent
studies have demonstrated that the abnormal expression of GIRK4
gene is associated with AF and may be closely related to obesity, MS,
and many other clinical conditions [155]. Future directions in the
ﬁeld of genetics and genomics include gene–environment interac-
tion relating to obesity-years, genetic expression and AF risk, as well
as relation of microRNA expression in AF to obesity-years [156].
Conclusion
In conclusion, the epidemic of obesity appears to feed the
epidemic of AF. The pathophysiological mechanisms of this
association are complex and many pathways remain elusive.
Besides general measures for obesity prevention and management,
and treatment of comorbidities, future studies may reveal mole-
cular targets that could lead to speciﬁc therapeutic interventions.
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